ZL-1503 Shows Promise as First-in-Class Treatment at IMMUNOLOGY2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy ZLAB?
Source: Newsfilter
- Efficacy Data Presentation: At IMMUNOLOGY2026, Zai Lab showcased ZL-1503's sustained inhibition of IL-31-induced itching and IL-13 signaling over 112 days, indicating its potential as a first-in-class treatment for moderate-to-severe atopic dermatitis, which could transform patient treatment options.
- Favorable Safety Profile: ZL-1503 demonstrated a strong nonclinical safety profile across all studies, supporting its advancement into human clinical trials, which is expected to offer patients a safer treatment option and reduce dosing frequency compared to current biologics.
- Clinical Trial Initiation: Zai Lab initiated Phase 1 clinical trials for ZL-1503 in December 2025, with clinical data anticipated in the second half of 2026, laying the groundwork for market introduction and enhancing the company's competitive position in the biopharmaceutical sector.
- In-Depth Mechanistic Research: Studies indicate that ZL-1503 can simultaneously suppress inflammatory and pruritic pathways associated with atopic dermatitis, providing robust mechanistic evidence that supports its strategic significance as a novel therapeutic option.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZLAB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZLAB
Wall Street analysts forecast ZLAB stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 24.190
Low
25.70
Averages
47.93
High
74.00
Current: 24.190
Low
25.70
Averages
47.93
High
74.00
About ZLAB
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zai Lab Partners with Amgen to Evaluate Lung Cancer Therapy
- Global Clinical Trial Collaboration: On April 1, Zai Lab entered into a global clinical trial collaboration with Amgen to evaluate a combination therapy for extensive-stage small cell lung cancer, showcasing strategic synergy in oncology treatment between the two companies.
- Dual-Targeting Strategy: The study will combine Zai Lab's zocilurtatug pelitecan with Amgen's IMDELLTRA, aiming to enhance clinical responses and address potential resistance pathways through complementary mechanisms, thereby improving survival chances for patients.
- Clinical Trial Progress: Zocilurtatug pelitecan has demonstrated a high response rate and a tolerable safety profile in heavily pretreated SCLC patients, indicating its therapeutic potential, especially with FDA orphan drug and fast track designations.
- New Treatment Paradigm: By combining the first-ever approved DLL3-targeting bispecific therapy, Zai Lab and Amgen aim to establish a new treatment paradigm for one of the most aggressive and lethal forms of solid tumors.
See More
ZL-1503 Shows Promise as First-in-Class Treatment at IMMUNOLOGY2026
- Efficacy Data Presentation: At IMMUNOLOGY2026, Zai Lab showcased ZL-1503's sustained inhibition of IL-31-induced itching and IL-13 signaling over 112 days, indicating its potential as a first-in-class treatment for moderate-to-severe atopic dermatitis, which could transform patient treatment options.
- Favorable Safety Profile: ZL-1503 demonstrated a strong nonclinical safety profile across all studies, supporting its advancement into human clinical trials, which is expected to offer patients a safer treatment option and reduce dosing frequency compared to current biologics.
- Clinical Trial Initiation: Zai Lab initiated Phase 1 clinical trials for ZL-1503 in December 2025, with clinical data anticipated in the second half of 2026, laying the groundwork for market introduction and enhancing the company's competitive position in the biopharmaceutical sector.
- In-Depth Mechanistic Research: Studies indicate that ZL-1503 can simultaneously suppress inflammatory and pruritic pathways associated with atopic dermatitis, providing robust mechanistic evidence that supports its strategic significance as a novel therapeutic option.
See More
Zoci Antibody Drug Shows Promising Efficacy in Small Cell Lung Cancer
- Clinical Trial Results: Zoci demonstrated a 53.7% confirmed intracranial objective response rate (iORR) in small cell lung cancer (SCLC) patients, with a remarkable 62.5% iORR (10/16) at a 1.6 mg/kg dose, indicating significant potential in treating difficult-to-treat cancers.
- Neuroendocrine Carcinoma Performance: Zoci showed a 38.2% confirmed objective response rate in patients with extrapulmonary neuroendocrine carcinomas (NECs), highlighting its antitumor activity across various malignancies and potentially providing new treatment options in this high-need area.
- Global Clinical Trial Progress: A global Phase 3 trial for Zoci is ongoing for second-line-plus SCLC treatment, with plans to advance to the registrational phase by 2026, laying a foundation for future market expansion for Zai Lab.
- Investor Conference Arrangement: Zai Lab is set to hold an investor conference call on April 20, 2026, to discuss data presented at the AACR Annual Meeting and clinical trial plans, further enhancing investor confidence in the company's R&D progress.
See More
Zai Lab Partners with Amgen for Global Clinical Trial
- Global Clinical Trial Collaboration: Zai Lab announced a collaboration with Amgen to conduct a global clinical trial studying its antibody-drug conjugate zocilurtatug pelitecan in combination with Amgen's bispecific T-cell engager Imdelltra, marking a strategic move in the small cell lung cancer space.
- Clinical Trial Phase: Amgen will sponsor a global Phase 1b study to evaluate the drug combination in patients with extensive-stage small cell lung cancer, which accounts for about two-thirds of SCLC cases, indicating the potential market size of this collaboration.
- Ownership and Supply of Drug: Zai Lab will retain full ownership of zocilurtatug pelitecan and supply the experimental therapy for the Amgen-led study, ensuring control over the development process while potentially enhancing its market competitiveness.
- Market Outlook for SCLC: Small cell lung cancer accounts for 15% of nearly 2.5 million lung cancer cases diagnosed globally each year, with extensive-stage SCLC having high relapse rates and poor prognosis, highlighting the urgent need for new therapies, and Zai Lab's collaboration aims to address this market gap.
See More
Zai Lab Collaborates with Amgen for Clinical Trial
- Clinical Collaboration Agreement: Zai Lab has entered into a global clinical trial collaboration with Amgen to evaluate the safety and efficacy of DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan in combination with IMDELLTRA®, marking a strategic move in the treatment of small cell lung cancer.
- Global Study Launch: Amgen will sponsor a global Phase 1b study while Zai Lab retains full ownership of zocilurtatug pelitecan, which is expected to drive the development of new therapies and enhance the company's competitiveness in the oncology market.
- Efficacy Potential: Zocilurtatug pelitecan has demonstrated a high response rate at the EORTC-NCI-AACR and ASCO meetings, particularly showing significant intracranial activity in heavily pretreated small cell lung cancer patients, potentially offering new treatment options for this challenging disease.
- Market Outlook: With poor prognosis for small cell lung cancer patients, and IMDELLTRA® already FDA-approved, the combination of zocilurtatug pelitecan and IMDELLTRA® is poised to further improve efficacy, addressing the urgent market demand for new therapies.
See More
Zai Lab Showcases Innovative ADCs at AACR 2026
- Drug Presentation: Zai Lab's ADCs ZL-6201 and ZL-1222 will be showcased at the 2026 AACR Annual Meeting, highlighting their potential in treating sarcomas and solid tumors, which is expected to attract investor interest and enhance the company's market profile.
- Clinical Trial Progress: Zoci's clinical trials for small cell lung cancer demonstrate promising intracranial responses, with plans for three registration-enabling studies by the end of 2026, potentially establishing it as the first global oncology launch for the company and solidifying its leadership in cancer treatment.
- Innovative Treatment Strategy: ZL-6201, as the first LRRC15-targeting ADC, shows promise for multiple solid tumors, potentially transforming existing treatment standards and improving patient survival rates, thereby enhancing the company's market position.
- New Direction in Immunotherapy: ZL-1222 aims to overcome PD-1 resistance as a next-generation immunocytokine therapy, enhancing antitumor immunity; if successful, it could open new revenue streams and strengthen the company's competitive edge in the immunotherapy sector.
See More
Zai Lab Partners with Amgen to Evaluate Lung Cancer Therapy
- Global Clinical Trial Collaboration: On April 1, Zai Lab entered into a global clinical trial collaboration with Amgen to evaluate a combination therapy for extensive-stage small cell lung cancer, showcasing strategic synergy in oncology treatment between the two companies.
- Dual-Targeting Strategy: The study will combine Zai Lab's zocilurtatug pelitecan with Amgen's IMDELLTRA, aiming to enhance clinical responses and address potential resistance pathways through complementary mechanisms, thereby improving survival chances for patients.
- Clinical Trial Progress: Zocilurtatug pelitecan has demonstrated a high response rate and a tolerable safety profile in heavily pretreated SCLC patients, indicating its therapeutic potential, especially with FDA orphan drug and fast track designations.
- New Treatment Paradigm: By combining the first-ever approved DLL3-targeting bispecific therapy, Zai Lab and Amgen aim to establish a new treatment paradigm for one of the most aggressive and lethal forms of solid tumors.
See More
ZL-1503 Shows Promise as First-in-Class Treatment at IMMUNOLOGY2026
- Efficacy Data Presentation: At IMMUNOLOGY2026, Zai Lab showcased ZL-1503's sustained inhibition of IL-31-induced itching and IL-13 signaling over 112 days, indicating its potential as a first-in-class treatment for moderate-to-severe atopic dermatitis, which could transform patient treatment options.
- Favorable Safety Profile: ZL-1503 demonstrated a strong nonclinical safety profile across all studies, supporting its advancement into human clinical trials, which is expected to offer patients a safer treatment option and reduce dosing frequency compared to current biologics.
- Clinical Trial Initiation: Zai Lab initiated Phase 1 clinical trials for ZL-1503 in December 2025, with clinical data anticipated in the second half of 2026, laying the groundwork for market introduction and enhancing the company's competitive position in the biopharmaceutical sector.
- In-Depth Mechanistic Research: Studies indicate that ZL-1503 can simultaneously suppress inflammatory and pruritic pathways associated with atopic dermatitis, providing robust mechanistic evidence that supports its strategic significance as a novel therapeutic option.
See More
Zoci Antibody Drug Shows Promising Efficacy in Small Cell Lung Cancer
- Clinical Trial Results: Zoci demonstrated a 53.7% confirmed intracranial objective response rate (iORR) in small cell lung cancer (SCLC) patients, with a remarkable 62.5% iORR (10/16) at a 1.6 mg/kg dose, indicating significant potential in treating difficult-to-treat cancers.
- Neuroendocrine Carcinoma Performance: Zoci showed a 38.2% confirmed objective response rate in patients with extrapulmonary neuroendocrine carcinomas (NECs), highlighting its antitumor activity across various malignancies and potentially providing new treatment options in this high-need area.
- Global Clinical Trial Progress: A global Phase 3 trial for Zoci is ongoing for second-line-plus SCLC treatment, with plans to advance to the registrational phase by 2026, laying a foundation for future market expansion for Zai Lab.
- Investor Conference Arrangement: Zai Lab is set to hold an investor conference call on April 20, 2026, to discuss data presented at the AACR Annual Meeting and clinical trial plans, further enhancing investor confidence in the company's R&D progress.
See More
Zai Lab Partners with Amgen for Global Clinical Trial
- Global Clinical Trial Collaboration: Zai Lab announced a collaboration with Amgen to conduct a global clinical trial studying its antibody-drug conjugate zocilurtatug pelitecan in combination with Amgen's bispecific T-cell engager Imdelltra, marking a strategic move in the small cell lung cancer space.
- Clinical Trial Phase: Amgen will sponsor a global Phase 1b study to evaluate the drug combination in patients with extensive-stage small cell lung cancer, which accounts for about two-thirds of SCLC cases, indicating the potential market size of this collaboration.
- Ownership and Supply of Drug: Zai Lab will retain full ownership of zocilurtatug pelitecan and supply the experimental therapy for the Amgen-led study, ensuring control over the development process while potentially enhancing its market competitiveness.
- Market Outlook for SCLC: Small cell lung cancer accounts for 15% of nearly 2.5 million lung cancer cases diagnosed globally each year, with extensive-stage SCLC having high relapse rates and poor prognosis, highlighting the urgent need for new therapies, and Zai Lab's collaboration aims to address this market gap.
See More
Zai Lab Collaborates with Amgen for Clinical Trial
- Clinical Collaboration Agreement: Zai Lab has entered into a global clinical trial collaboration with Amgen to evaluate the safety and efficacy of DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan in combination with IMDELLTRA®, marking a strategic move in the treatment of small cell lung cancer.
- Global Study Launch: Amgen will sponsor a global Phase 1b study while Zai Lab retains full ownership of zocilurtatug pelitecan, which is expected to drive the development of new therapies and enhance the company's competitiveness in the oncology market.
- Efficacy Potential: Zocilurtatug pelitecan has demonstrated a high response rate at the EORTC-NCI-AACR and ASCO meetings, particularly showing significant intracranial activity in heavily pretreated small cell lung cancer patients, potentially offering new treatment options for this challenging disease.
- Market Outlook: With poor prognosis for small cell lung cancer patients, and IMDELLTRA® already FDA-approved, the combination of zocilurtatug pelitecan and IMDELLTRA® is poised to further improve efficacy, addressing the urgent market demand for new therapies.
See More
Zai Lab Showcases Innovative ADCs at AACR 2026
- Drug Presentation: Zai Lab's ADCs ZL-6201 and ZL-1222 will be showcased at the 2026 AACR Annual Meeting, highlighting their potential in treating sarcomas and solid tumors, which is expected to attract investor interest and enhance the company's market profile.
- Clinical Trial Progress: Zoci's clinical trials for small cell lung cancer demonstrate promising intracranial responses, with plans for three registration-enabling studies by the end of 2026, potentially establishing it as the first global oncology launch for the company and solidifying its leadership in cancer treatment.
- Innovative Treatment Strategy: ZL-6201, as the first LRRC15-targeting ADC, shows promise for multiple solid tumors, potentially transforming existing treatment standards and improving patient survival rates, thereby enhancing the company's market position.
- New Direction in Immunotherapy: ZL-1222 aims to overcome PD-1 resistance as a next-generation immunocytokine therapy, enhancing antitumor immunity; if successful, it could open new revenue streams and strengthen the company's competitive edge in the immunotherapy sector.
See More
